je.st
news
Home
› MIV-247 Has Been Selected As A Candidate Drug And Enters Development For The Treatment Of Neuropathic Pain
MIV-247 Has Been Selected As A Candidate Drug And Enters Development For The Treatment Of Neuropathic Pain
2013-10-30 05:30:13| drugdiscoveryonline News Articles
Medivir AB (OMX:MVIR) announced that MIV-247 has been selected as a candidate drug (CD) from its cathepsin S inhibitor project for the treatment of neuropathic pain, and is entering non-clinical development
Tags: the
of
development
selected
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||